New hope: targeted drug olaparib shows promise for Hard-to-Treat breast cancers
NCT ID NCT03344965
First seen Jan 08, 2026 · Last updated May 09, 2026 · Updated 16 times
Summary
This study tests a drug called olaparib in people with metastatic breast cancer that has spread beyond the breast. Participants must have a specific gene mutation that makes their cancer cells less able to repair DNA damage. The goal is to see if olaparib can shrink tumors or slow the disease. About 114 adults are taking part in this phase 2 trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02115, United States
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University
Durham, North Carolina, 27708, United States
-
Indiana University
Indianapolis, Indiana, 46202, United States
-
Johns Hopkins University
Baltimore, Maryland, 21218, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Cancer Center Basking Ridge
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Cancer Center Bergen
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center Commack
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Cancer Center Monmouth
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Cancer Center Nassau
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering Cancer Center Westchester
East White Plains, New York, 10604, United States
-
UPMC Hillman Cancer Center - Erie
Erie, Pennsylvania, 16505, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
-
University of California, San Francisco
San Francisco, California, 94143, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of Pittsburgh
Pittsburgh, Pennsylvania, 15260, United States
-
University of Washington Fred Hutchinson Cancer Care
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.